作者: Kuo-Chen Wei , Po-Chun Chu , Hay-Yan Jack Wang , Chiung-Yin Huang , Pin-Yuan Chen
DOI: 10.1371/JOURNAL.PONE.0058995
关键词: Blood–brain barrier 、 Magnetic resonance imaging 、 Temozolomide 、 Brain tumor 、 Pathology 、 Cerebrospinal fluid 、 Brain damage 、 Microbubbles 、 Tumor progression 、 Medicine 、 General Biochemistry, Genetics and Molecular Biology 、 General Agricultural and Biological Sciences 、 General Medicine
摘要: The purpose of this study is to assess the preclinical therapeutic efficacy magnetic resonance imaging (MRI)-monitored focused ultrasound (FUS)-induced blood-brain barrier (BBB) disruption enhance Temozolomide (TMZ) delivery for improving Glioblastoma Multiforme (GBM) treatment. MRI-monitored FUS with microbubbles was used transcranially disrupt BBB in brains Fisher rats implanted 9L glioma cells. FUS-BBB opening spectrophotometrically determined by leakage dyes into brain, and TMZ quantitated cerebrospinal fluid (CSF) plasma LC-MS\MS. effects treatment on tumor progression (by MRI), animal survival brain tissue histology were investigated. Results demonstrated that increased local accumulation parenchyma 3.8-/2.1-fold normal/tumor tissues. Compared alone, combined CSF/plasma ratio from 22.7% 38.6%, reduced 7-day 24.03 5.06, extended median 20 23 days. In conclusion, provided evidence BBB-opening concentration improve control survival, suggesting its clinical potential current